Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma

Patients with locally advanced and metastatic urothelial carcinoma have a low survival rate (median 15.7 months, 13.1–17.8), with only a 23% response rate to monotherapy treatment with anti-PDL1 checkpoint immunotherapy. To identify new therapeutic targets, we profiled the immune regulatory signatur...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Podojil, Joseph R., Glaser, Alexander P., Baker, Dylan, Courtois, Elise T., Fantini, Damiano, Yu, Yanni, Eaton, Valerie, Sivajothi, Santhosh, Chiang, Mingyi, Das, Arighno, McLaughlin, Kimberly A., Robson, Paul, Miller, Stephen D., Meeks, Joshua J.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7185218/
https://ncbi.nlm.nih.gov/pubmed/32363111
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1744897
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados